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Abstract
Gonadotropin releasing hormone-III (GnRH-III), a native isoform of the human GnRH isolated from sea lamprey, specifically
binds to GnRH receptors on cancer cells enabling its application as targeting moieties for anticancer drugs. Recently, we reported
on the identification of a novel daunorubicin–GnRH-III conjugate (GnRH-III–[4Lys(Bu), 8Lys(Dau=Aoa)] with efficient in vitro
and in vivo antitumor activity. To get a deeper insight into the mechanism of action of our lead compound, the cellular uptake was
followed by confocal laser scanning microscopy. Hereby, the drug daunorubicin could be visualized in different subcellular com-
partments by following the localization of the drug in a time-dependent manner. Colocalization studies were carried out to prove the
presence of the drug in lysosomes (early stage) and on its site of action (nuclei after 10 min). Additional flow cytometry studies
demonstrated that the cellular uptake of the bioconjugate was inhibited in the presence of the competitive ligand triptorelin indicat-
ing a receptor-mediated pathway. For comparative purpose, six novel daunorubicin–GnRH-III bioconjugates have been synthe-
sized and biochemically characterized in which 6Asp was replaced by D-Asp, D-Glu and D-Trp. In addition to the analysis of the in
vitro cytostatic effect and cellular uptake, receptor binding studies with 125I-triptorelin as radiotracer and degradation of the GnRH-
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III conjugates in the presence of rat liver lysosomal homogenate have been performed. All derivatives showed high binding affini-
ties to GnRH receptors and displayed in vitro cytostatic effects on HT-29 and MCF-7 cancer cells with IC50 values in a low micro-
molar range. Moreover, we found that the release of the active drug metabolite and the cellular uptake of the bioconjugates were
strongly affected by the amino acid exchange which in turn had an impact on the antitumor activity of the bioconjugates.
Introduction
Cancer is one of the most serious diseases worldwide and
malignant tumors and metastases often lead to high mortality.
Chemotherapy is a widely used method to treat cancerous
diseases, but the lack of selectivity, drug-specific side-effects
and toxicity to healthy tissues result in various complications,
which restrict the application of chemotherapeutics. A promis-
ing treatment option to overcome these drawbacks can be
targeted tumor therapy. This approach is based on the fact that
receptors for many regulatory ligands such as peptide hormones
are overexpressed on the surface of various cancer cells includ-
ing gonadotropin-releasing hormone receptors (GnRH-R) [1].
Therefore, these peptides are suitable for specific drug targeting
to tumor cells. The native ligand of this receptor is GnRH-I
(<EHWSYGLRPG-NH2, where <E is pyroglutamic acid) which
is synthesized and released within the hypothalamus. GnRH
stimulates the synthesis and release of the regulatory pituitary
glycoprotein luteinizing hormone (LH) and follicle stimulating
hormone (FSH) which act on the gonads and regulate the pro-
duction of the sex steroids androgen and estrogen [2].
In the last decades a large number of synthetic GnRH-I-ana-
logues has been designed with the purpose to interact with the
receptor and influence the release of pituitary gonadotropins LH
and FSH [1,3-6]. The replacement of 6Gly by D-amino acids in
human GnRH-I provides superagonists like the GnRH-I deriva-
t ives buserel in [6D-Ser( t-Bu),  9Pro-EA],  goserel in
[6D-Ser(t-Bu), 10Azagly-NH2], leuprolide [6D-Leu, 9Pro-EA]
and triporelin [6D-Trp], which are used as pharmaceutical
peptides to treat inter alia hormone dependent prostate and/or
breast cancer [7].
Since the mid-1980s cytotoxic GnRH-I derivatives were de-
veloped and investigated to treat tumor cells [4,5,8,9]. Anthra-
cyclines such as doxorubicin (Dox), daunorubicin (Dau) or
epirubicin are frequently used anticancer drugs. Their mode of
action is based on a planar ring system which is important for
intercalation into DNA [10]. In this way, anthracyclines can
affect a broad range of DNA processes leading to an inhibited
synthesis of macromolecules such as mRNA and DNA [10,11].
More precisely, anthracyclines act as topoisomerase II toxins
inhibiting DNA transcription and replication. They stabilize a
DNA topoisomerase-II intermediate in which the DNA strands
are separated and a specific tyrosine residue of the topoisomer-
ase II is covalently linked to the DNA by formation of a
tyrosine phosphodiester [10-12]. Moreover, anthracyclines
provide a beneficial auto-fluorescence allowing the perfor-
mance of fluorescence based studies like confocal laser scan-
ning microscopy (CLSM) and fluorescence-activated cell
sorting (FACS) to investigate the cellular uptake and the subcel-
lular localization of the drug or the drug bioconjugates [13,14].
It is well known from the literature that anthracyclines accumu-
late in the nucleus, in that manner they also act as DNA stains
[14,15].
The first cytotoxic GnRH-I derivative, which was investigated
in preclinical and clinical studies, was zoptarelin-doxorubicin
also known as AEZS-108 (previously AN-152) [16]. The
anthracycline doxorubicin was conjugated to the ε-amino group
of GnRH-I-[6D-Lys] by insertion of a glutaric acid linker. The
resulting ester bond can be cleaved by carboxylesterases,
leading to the release of the cytotoxic agent within the tumor
cell. During clinical trials, only mild side effects were observed
which are caused by premature drug release [17]. The receptor
mediated uptake of zoptarelin has been investigated by
blockage of GnRH receptors using an excess of the GnRH-I
superagonist triptorelin [14]. In addition, the internalization and
the intracellular localization of AN-152 were visualized by
CLSM [14]. Despite all these promising findings, zoptarelin-
doxorubicin did not achieve its primary endpoint in phase 3
clinical studies on endometrial cancer [18].
A natural isoform of the human GnRH-I, the sea lamprey ana-
logue GnRH-III (<EHWSHDWKPG-NH2), was identified and
characterized by Sower et al. [19]. Due to the significantly
lower endocrine effect compared to GnRH-I and the specific
binding to GnRH-Rs on cancer cells, GnRH-III might have
advantage as a carrier for cytotoxic drugs, especially in case of
hormone-independent tumors [20]. Based on these findings,
GnRH-III has been used as an efficient homing device for
targeted tumor therapy [21,22]. Moreover, it was demonstrated
that a modification of the side chain of 8Lys did not hinder the
receptor binding or the antiproliferative activity. Furthermore,
the absence of the free ε-amino group additionally reduced the
endocrine effect [23,24]. Thus, the 8Lys can be utilized as
conjugation site for cytotoxic agents like anthracyclines. In the
past decade, a variety of different linkage systems has been
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carried out including ester or hydrazine bonds, cathepsin-B
labile spacers and oxime bonds [21,22,25].
Due to its structural properties, Dau cannot be attached to the
homing device by an ester bond like Dox, because of the
absence of the primary hydroxy group in position C-14. Howev-
er, the C-13 carbonyl group of Dox/Dau provides a suitable
conjugation site and can be used for the formation of oximes.
We have recently reported that Dau was efficiently linked to the
8Lys side-chain by incorporation of an aminooxyacetic acid
(Aoa) moiety [21,25]. The formed oxime linkage is more stable
under physiological conditions than the ester bond resulting in a
longer half-life of the conjugate during circulation. Neverthe-
less, the drug is released within the cancer cell by lysosomal en-
zymes, especially by cathepsin B, which leads to various
Dau containing metabolites [26]. In case of GnRH-
III–[8Lys(Dau=Aoa)] conjugates the smallest Dau metabolite
obtained by lysosomal degradation is H-Lys(Dau=Aoa)-OH,
which is able to bind to DNA resulting in a cytotoxic effect. A
variety of oxime bond containing GnRH-III drug conjugates
have been designed in our research group and their in vitro
cytotoxic effects on hormone dependent human breast adeno-
carcinoma cancer cells (MCF-7) and on hormone independent
human colon carcinoma cells (HT-29) were analyzed
[22,25,27,28]. Thereby, it has been exposed, that an exchange
of 4Ser by 4Lys followed by acylation of the ε-amino group
with short chain fatty acids (SCFA) improved the cellular
uptake and the antitumor activity [29]. Moreover, these GnRH-
III bioconjugates displayed an enhanced stability in the pres-
ence of gastrointestinal enzymes. The most potent and efficient
bioconjugate which has been evaluated in in vitro cytostatic
effect measurements on human breast cancer cells (MCF7) and
human colon cancer cells (HT-29), is GnRH-III–[4Lys(Bu),
8Lys(Dau=Aoa)] (K2). Recent studies demonstrated that the
butyrilation of the lysine in position 4 not only leads to an in-
creased in vitro but also to an enhanced in vivo antitumor activ-
ity [29,30].
In order to achieve a better understanding of the mechanism of
action, the internalization and the intracellular localization, our
lead compound K2 was studied and monitored by CLSM.
Furthermore, the cellular uptake of K2 was evaluated in compe-
tition with the GnRH-I superagonist triptorelin by flow cytom-
etry indicating a receptor mediated pathway.
To gain further information about sequence–activity relation-
ship of GnRH-III, we studied the impact of 6Asp on the effi-
ciency of tumor targeting. Since it is known from the literature
that an incorporation of D-amino acids (D-Aaa) in position 6 of
GnRH-I and II peptides can lead to an improved receptor
binding affinity and an enhanced antiproliferative activity with-
Scheme 1: Syntheses of GnRH-III–[(4Lys(Bu)/4Ser, 6Aaa,
8Lys(Dau=Aoa)] bioconjugates. a) (1) 2% hydrazine in DMF
12 × 5 min; (2) 3 equiv butyric anhydride, 3 equiv DIPEA in DMF, 2 h.
b) (1) 2% TFA in DCM, 6 × 5 min; (2) 10% DIPEA in DCM, 3 × 5 min;
(3) 3 equiv Boc-Aoa-OH, 3 equiv HOBt, 3 equiv DIC in DMF, 1 h;
(4) 95% TFA, 2.5% TIS, 2.5% H2O, 10 equiv H-Aoa-OH, 2h.
c) 1.3 equiv Dau in 0.1 M NH4OAc buffer (pH 5), overnight. Fmoc:
9-fluorenylmethoxycarbonyl, SPPS: solid-phase peptide synthesis,
Dde: 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl, Mtt: 4-methyl-
trityl, Bu: butyryl, Aoa: aminooxyacetyl, Dau: daunorubicin, blue circle:
Rink amide MBHA-resin.
out substantial effect on the endocrine activity [31-33], we de-
veloped six novel GnRH-III–Dau conjugates in which the 6Asp
was replaced by D-Aaa. Here we report on the synthesis of
GnRH-III bioconjugates containing D-Asp, D-Glu or D-Trp in
position 6 and Ser or Lys(Bu) in position 4. Moreover, the
novel GnRH-III–Dau conjugates were compared systematically
with our lead compound K2 in terms of in vitro cytostatic
effect, receptor binding affinity, cellular uptake and lysosomal
digestion in the presence of rat liver lysosomal homogenate.
Results and Discussion
Synthesis of oxime bond-linked
GnRH-III–[4Ser/Lys(Bu), 6Aaa,
8Lys(Dau=Aoa)] bioconjugates
The GnRH-III bioconjugates were prepared as shown in
Scheme 1. All peptides were synthesized by standard Fmoc-
SPPS using orthogonal lysine protecting groups. Fmoc-
Lys(Dde)-OH was incorporated in position 4 and Fmoc-
Lys(Mtt)-OH in position 8. After peptide chain elongation the
Dde group was removed and 4Lys was butyrylated by using
butyric anhydride. Afterwards, the Mtt group was cleaved under
mild acidic conditions, followed by Boc-Aoa-OH coupling.
After cleavage from the resin with an appropriate TFA–scav-
enger mixture and purification of the crude compounds by
preparative HPLC, the attachment of daunorubicin via oxime
Beilstein J. Org. Chem. 2018, 14, 756–771.
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Table 1: Chemical characteristics of Dau–GnRH-III bioconjugates.
Code [8Lys(Dau=Aoa)]–GnRH-III compound Purity [%] RP-HPLC tR [min]a ESIMS MWcal/MWexp [g/mol]b Yield [%]c
K1 [6L-Asp] >97 27.8 1841.89/1841.66 22
1 [6D-Asp] >96 28.0 1841.89/1841.60 8
2 [6D-Glu] >98 29.2 1855.91/1855.70 14
3 [6D-Trp] >95 32.5 1913.01/1912.80 7
K2 [4Lys(Bu),6L-Asp] >97 29.3 1953.071952.79 27
4 [4Lys(Bu),6D-Asp] >98 29.5 1953.07/1952.90 9
5 [4Lys(Bu),6D-Glu] >96 29.7 1966.93/1966.70 7
6 [4Lys(Bu),6D-Trp] >97 32.6 2024.03/2023.70 6
aColumn: Phenomenex Luna C18 column (250 mm × 4.6 mm) with 5 µm silica (100 Å pore size); gradient: 0 min 0% B, 5 min 0% B, 50 min 90% B;
eluents: 0.1% TFA in water (A) and 0.1% TFA in acetonitrile/water (80:20, v/v) (B); flow rate: 1 mL/min; detection at 220 nm. bBruker Daltonics
Esquire 3000+ ion trap mass spectrometer. cYield over all synthetic and purification steps.
linkage was carried out in solution as previously reported [21].
The resulting GnRH-III–Dau conjugates were purified by
preparative HPLC, the final products K1, K2 and 1–6 were
characterized by analytical HPLC and mass spectrometry
(Table 1, Supporting Information File 1, Figures S1–S8). The
bioconjugates could be obtained in yields up to 27% over all
synthesis and purification steps. The lower yields of the
D-amino acid containing derivatives, especially in case of
D-Trp are related mainly to their decreased solubility compared
to the parent compounds. Moreover, the free aminooxy group is
highly reactive towards aldehydes and ketones leading to the
formation of unwanted side-products [34]. Aminooxy acety-
lated peptides prone to react with traces of acetone or formalde-
hyde (e.g., from the softeners of the plastic tubes) not only
during the reaction steps (cleavage, ligation) but also under the
HPLC purification conditions which has a high impact on the
yield [35].
Secondary structure determination by
electronic circular dichroism spectroscopy
ECD spectra of GnRH-III–[4Ser/4Lys(Bu), 6D/L-Asp,
8Lys(Dau=Aoa)] (K1, K2, 1 and 4) were measured in aqueous
solution to study the influence of the exchange of L-Asp to
D-Asp in position 6 on the peptide conformation. The D-Trp
containing analogs were not soluble under this condition, while
we did not expect significant influence of ECD spectra from the
exchange of D-Asp to D-Glu. The ECD spectra of all four
GnRH-III peptide conjugates reveal two distinct bands: one
negative at 200 nm and one positive at 235 nm (Figure 1, Sup-
porting Information File 1, Figures S15 and S16). The negative
band is also present in the GnRH-III peptide without the
daunorubicin (Dau) part. This indicates that the main conforma-
tional preferences are not changed by the conjugation. The
shapes of the ECD curves show a highly dynamic peptide struc-
ture in water. This is in agreement with the NMR study made
by Pappa et al. that presented an extended and more flexible
structure of GnRH-III than GnRH-I which has rather more
defined U-shape structure [36]. In case of the positive band
(235 nm) we can conclude that this is a contribution of the Dau
part of the molecules because it has a positive band near 230 nm
and in the conjugates this band is shifted to 235 nm. The Dau
has also a negative band at 200 nm.
Figure 1: Far-UV ECD spectra of GnRH-III and its drug conjugates in
water (GnRH-III solid, K1 dash, K2 dot, 1 dash dot, 4 dash dot dot).
Insert: far-UV ECD spectra of daunorubicin.
The only difference between the D-Asp derivatives and the
original peptides is located near 215 nm. This sign indicates the
presence of increased contribution of β-sheet like secondary
structure in case of D-Asp derivatives. Because no aggregation
could be observed in HPLC or MS measurements, we assume
that the presence of the β-hairpin structure is a feasible concep-
tion in these cases.
Stability/degradation of the GnRH-III
bioconjugates
Drug delivery systems (DDS) are promising therapeutics for
tumor therapy providing a selective application to tumor cells
Beilstein J. Org. Chem. 2018, 14, 756–771.
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and a reduction of toxic side effects. To ensure these benefits,
stability and degradation studies are of great importance during
DDS development. In vitro degradation studies in the presence
of gastrointestinal enzymes and lysosomal homogenate as well
as stability analyses in human serum provide valuable informa-
tion [37]. On the one hand toxic side effects caused by prema-
ture drug release should be avoided, on the other hand an intra-
cellular drug release from the bioconjugates in the targeted cell
is mandatory to assure the antitumor activity. Previously, we re-
ported on the stability of the bioconjugates GnRH-
III–[8Lys(Dau=Aoa)] (K1) and GnRH-III–[4Lys(Ac),
8Lys(Dau=Aoa)] in 90% human serum and in the presence of
digestive enzymes trypsin and α-chymotrypsin [26,38]. It was
found that both Dau–GnRH-III compounds were stable in
human serum and trypsin at 37 °C for at least 24 h. Further-
more, the incorporation of an acetylated lysine instead of the
native serine in position 4 decelerated the degradation by
α-chymotrypsin which catalyzed the hydrolysis of the peptide
bond exclusively between 3Trp and 4Aaa. A similar effect was
observed for GnRH-III conjugates in which the ε-amino group
of 4Lys was acylated by different SCFAs. It is worth to mention
that the main cleavage sites of GnRH peptides by different en-
zymes are at both sides of serine in position 4 [39,40], that can
be prohibited by replacement of Ser with an acylated lysine.
Moreover, it has been shown that the stability is increased with
the length of the side chain modification [29]. In this manner,
the bioconjugate GnRH-III–[4Lys(Bu), 8Lys(Dau=Aoa)] (K2)
displayed a two-fold higher stability in the presence of
α-chymotrypsin than GnRH-III–[4Lys(Ac), 8Lys(Dau=Aoa)]
[29,38].
The novel GnRH-III bioconjugates 1–6 have been analyzed for
their stability/degradation in cell culture medium and in the
presence of rat liver lysosomal homogenate. Reaction mixtures
were incubated for 24 h at 37 °C, samples were taken at differ-
ent time points and analyzed by analytical RP-HPLC and
LC–MS. The approved bioconjugates K1 and K2 were
analyzed in the same manner and the achieved results were used
for a comparative evaluation of the novel GnRH-III–Dau conju-
gates.
The stability studies in cell culture medium revealed that all
compounds were stable at 37 °C for 24 h which is in accor-
dance with our previous results [29]. During this time, no de-
composition of the conjugates was observed, demonstrating that
no free drug or small drug containing metabolite was produced
in medium during the treatment that might have influence on
the in vitro biological assays.
Besides stability under physiological conditions, the release of
the drug within cancer cells is of high relevance. In this study
the anthracycline daunorubicin was used as anticancer agent.
This drug interacts with DNA by intercalation and affects a
broad range of DNA processing [11,41]. Orbán et al. recently
reported that next to the free drug, also small Dau-containing
metabolites revealed an antitumor activity [26,42].
In order to gain insight into the cellular release of the drug, the
degradation of the Dau–GnRH-III derivatives 1–6, K1 and K2
was determined in the presence of rat liver lysosomal
homogenate at 37 °C. As shown in Figure 2, all GnRH-III–Dau
peptides were digested by lysosomal enzymes resulting in
various peptide fragments (Supporting Information File 1, Table
S1). However, the degradation level and the cleavage sites
within the GnRH-III sequence differ considerably depending on
the incorporated amino acids, whereby the hydrolyses of the
C-terminus (H-Gly-NH2 and H-Pro-Gly-NH2) occurred first in
all eight GnRH-III derivatives. Due to the high chemical and
enzymatic stability of the oxime bond, no free Dau was detected
by LC–MS. In accordance with our previous results, the diges-
tion of the two peptides containing L-Asp in position 6 (K1,
K2) provided the smallest Dau-containing metabolite
(H-Lys(Dau=Aoa)-OH, m/z 729.36 [M + H]+). This metabolite
could already be detected after 1 hour of incubation in case of
K2 and after 2 hours in case of K1. The 6D-Asp containing
counterparts 1 and 4 exhibited higher lysosomal stabilities
preventing the release of H-Lys(Dau=Aoa)-OH. On the con-
trary, the fragment H-Lys(Dau=Aoa)-OH could be identified in
small amount after 24 h digestion of the bioconjugates 2 and 5
(6D-Glu). Surprisingly, in case of the 6D-Trp containing ana-
logues 3, 6, the effective metabolite was delivered much
faster (after 2 h 6 or 4 h 3) and in a higher amount (highlighted
peaks Figure 2C). Moreover,  the detected fragment
H-wWK(Dau=Aoa)-OH demonstrated that the D-Trp of conju-
gate 3 was accepted at the cleavage site of at least one lyso-
somal protease leading to improved release of the active
metabolite. It might be assumed that D-Trp of GnRH-
III–[4Lys(Bu), 6D-Tpr, 8Lys(Dau=Aoa)] (6) is also accepted at
the cleavage site, but due to the prior hydrolysis of the 7Trp-
8Lys(Dau=Aoa)-bond an evidential fragment has not been
detected. A reason for these diversities might be the subsite
specificities of the lysosomal proteases. For instance, lyso-
somal cysteine proteases also known as cathepsins show a
broad substrate specificity [43]. Nearly all human cysteine
proteases belong to the group of endopeptidases, whereby
cathepsin B is also a carboxydipeptidase and cathepsin X
displays carboxymono- and dipeptidase activity [44-46]. On the
contrary, cathepsin C functions as an aminodipeptidase and
cathepsin H reveals next to its endopeptidase activity also
aminomonopeptidase activity [44,46]. Due to the variety of the
detected fragments, we suggest that the rat liver homogenate
contained a similar mixture of homolog cathepsins. For
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Figure 2: Degradation of the GnRH-III bioconjugates by rat liver lysosomal homogenate. A) Cleavage sites produced by the proteolysis of bioconju-
gates in the presence of rat liver lysosomal homogenate (full-line arrows). B) Structure of the smallest Dau-containing metabolite and its correspond-
ing mass spectra (analysis of K1 after 24 h incubation at the retention time 16.2–16.6 min of the LC–MS chromatogram). C) LC–MS chromatogram of
the GnRH-III bioconjugates after 24 h of incubation with rat liver lysosomal homogenate at 37 °C (asterisk labeling peak of the smallest Dau-contain-
ing metabolite H-K(Dau=Aoa)-OH).
instance, the analyzed fragments of the 6L-Asp derivatives gave
clear hints for the presence of endopeptidases, while the diges-
tion of the 6D-Aaa compounds 1–3 gave only fragments which
evidence the activity of exomono- and/or dipeptidases. More-
over, the obtained results for the bioconjugates that contain
4Lys(Bu) (K2, 4–6) instead of serine indicate a proteolytic
cleavage by lysosomal endopeptidases, which might be of great
importance for the release of the smallest Dau-containing
metabolite.
Cytostatic effect of the bioconjugates
Cell lines often function as the first model system of choice to
study biological processes or to test the efficiency of drugs or
drug conjugates and their cytotoxic effects. Immortal cell lines
offer various benefits, for instance they are easy to handle, cost-
effective and provide consistent sample and reproducible results
[47]. Nevertheless, cell lines also present the disadvantage that
after a period of continuous growth, cell characteristics can
change and dedifferentiate in culture [47,48]. The serial
passaging can cause genotypic and phenotypic variations and
the state of confluency can also affect gene expression pattern
in some cell lines [47,49]. Due to this, the usage of internal
standards during the evaluation of new potential candidates
might be necessary to ensure comparability with previous
results. The cytostatic effect of the novel GnRH-III bioconju-
gates was determined on HT-29 human colon cancer and MCF-
7 human breast cancer cell lines by alamarBlue® assay. For a
better comparison, the well-studied bioconjugates GnRH-
III–[8Lys(Dau=Aoa)] (K1) and GnRH-III–[4Lys(Bu),
8Lys(Dau=Aoa)] (K2) were used as positive controls and
internal standards. The corresponding IC50 values were calcu-
lated by using nonlinear regression (sigmoidal dose response)
(Figure 3, Table 2). Unfortunately, the D-Trp containing com-
pounds 3 and 6 started to precipitate in both cell culture media
at higher concentrations limiting the concentration down to a
maximum of 10 µM. This effect could not be prevented by
using DMSO instead of ddH2O for the preparation of the stock
solutions. Unfortunately, the lower concentration range with a
maximum of 10 µM was not sufficient to achieve the dose-
response. Nevertheless, both D-Trp-containing compounds pro-
vided a decreased cell viability at the highest concentration
(10 µM) on HT-29 (58% (3) and 55% (6)) and MCF-7 cells
Beilstein J. Org. Chem. 2018, 14, 756–771.
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Figure 3: Cytostatic effect of the GnRH-III bioconjugates at different concentrations on A) HT-29 and B) MCF-7 cells after 24 h determined by alamar-
Blue® cell viability assay. Experiments were carried out by using four replicates with n = 2, error bars represent standard deviation. Curves obtained
by nonlinear regression (sigmoidal dose response). For IC50 values see Table 2.
Table 2: In vitro cytostatic effects of GnRH-III bioconjugates on HT-29 human colon cancer and MCF-7 human breast cancer cell line.
code [8Lys(Dau=Aoa)]–GnRH-III compound MCF-7 IC50 [µM] HT-29 IC50 [µM]
K1 [6L-Asp] 3.2 ± 0.1 1.5 ± 0.5
1 [6D-Asp] 13.0 ± 0.5 8.9 ± 1.3
2 [6D-Glu] 6.8 ± 1.0 10.1 ± 1.4
3 [6D-Trp] n.d.a n.d.a
K2 [4Lys(Bu),6L-Asp] 2.7 ± 0.1 1.9 ± 0.7
4 [4Lys(Bu),6D-Asp] 6.2 ± 0.2 9.3 ± 1.1
5 [4Lys(Bu),6D-Glu] 7.0 ± 1.2 13.7 ± 2.6
6 [4Lys(Bu),6D-Trp] n.d.a n.d.a
an.d. - no data (compound 3 and 6 precipitated in medium at concentrations higher than 20 µM – no dose response). All values represent mean ± SE.
(69% (3) and 53% (6)), demonstrating that all measured com-
pounds displayed an in vitro cytotoxic activity. Nevertheless,
the replacement of 6Asp by D-Asp, D-Glu or D-Trp led to a de-
creased cytostatic effect on the estimated cancer cell lines.
Considering the determined IC50 values, no relevant differ-
ences of the antiproliferative activity between the 4Ser and the
corresponding 4Lys(Bu) derivatives could be observed which is
not in line with our previous data [29]. This might be a result of
the prolonged incubation time which was modified from
6 hours up to 24 hours because of the decreased antitumor ac-
tivity of the novel compounds and the application of alamar-
Blue® instead of MTT assay. It can be assumed that the 4Ser
bioconjugates require a longer period of treatment to be fully
effective. The D-Glu containing GnRH-III derivatives 2 and 4
had slightly higher IC50 values on HT-29 cells than the D-Asp
Beilstein J. Org. Chem. 2018, 14, 756–771.
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Table 3: Competitive inhibition of [125I][6D-Trp]-GnRH-I binding to membranes of human pituitary and human prostate cancer specimens by GnRH-
III–Dau-conjugates.
IC50 [nM]
code [8Lys(Dau=Aoa)]–GnRH-III compound pituitary prostate cancer
K1 [6L-Asp] 6.3 ± 0.7 5.2 ± 0.6
1 [6D-Asp] 19.4 ± 2.8 8.9 ± 1.6
2 [6D-Glu] 23.5 ± 2.1 10.4 ± 1.3
3 [6D-Trp] n.d.a n.d.a
K2 [4Lys(Bu),6L-Asp] 3.9 ± 0.7 3.0 ± 1.1
4 [4Lys(Bu),6D-Asp] 6.1 ± 0.1 4.0 ± 1.3
5 [4Lys(Bu),6D-Glu] 7.9 ± 1.1 11.6 ± 2.0
6 [4Lys(Bu),6D-Trp] n.d.a n.d.a
an.d. - no data. All values represent mean ± SE.
compounds whereby the degradation profile of 2 and 4
displayed an enhanced release of the smallest Dau-containing
metabolite indicating that the GnRH-III bioconjugates vary in
their affinity for the GnRH-RI and/or their cellular uptake.
Radioligand binding studies
To investigate the binding affinity of the novel compounds to
the GnRH-receptor, an in vitro ligand competition assay has
been performed on human pituitary and GnRH-R positive
human prostate cancer tissues. Hereby, the displacement of
radiolabeled triptorelin by the unlabeled bioconjugates 1, 2, 4
and 5 was determined. For a better comparison, the bioconju-
gates K1 and K2 were also analyzed and used as reference. The
obtained results summarized in Table 3 point out that all
bioconjugates replaced [125I]-triptorelin with IC50 values in low
nanomolar range. With exception of conjugate 5 (7.9 nM and
11.6 nM), all evaluated compounds displayed slightly higher
binding affinity on human prostate cancer (3.0–10.4 nM) than
on human pituitary tissue (3.9–23.5 nM) being in accordance
with our previous observations [29]. The lowest ligand concen-
tration causing 50% inhibition of radioligand binding was ob-
tained for K2 with 3.9 nM on pituitary and 3.0 nM on prostate
cancer tissues which is only slightly higher than the reported
values for GnRH-I–[D-Lys6(Dau=Aoa)] (1.6 nM and 0.9 nM)
and GnRH-II–[D-Lys6(Dau=Aoa)] (4.2 nM and 2.1 nM)
[29,50].
Nevertheless, it has to be considered that the determined
IC50 values are within a narrow, low nanomolar range and do
not differ widely. Especially, the binding affinity on prostate
cancer tissue deviate only slightly (3.0–11.6 nm) indicating that
the incorporation of D-Asp or D-Glu in position 6 did not sub-
stantially affect the receptor binding properties of the GnRH-III
derivatives. In addition, the selectivity of conjugates 1, 2, 4 is a
bit higher toward the prostate cancer than the control conju-
gates K1 and K2. According to our data, the incorporation of
Lys(Bu) in position 4 instead of Ser increased the binding
affinity but lowered the selectivity of the conjugates.
All investigated GnRH-III derivatives inhibited the binding of
radiolabeled triptorelin efficiently by using increasing concen-
trations (1 pM to 1 µM). It has been reported that the GnRH-I
derivatives cetrorelix and buserelin displaced [125I]-triptorelin
completely by using the same concentration range, whereas
GnRH-unrelated peptides (e.g., somatostatin-14, bombesin)
could not inhibit the receptor binding at concentrations up to
1 µM [51,52]. Comparing our results with these findings from
literature we can assume that the analyzed GnRH-III–Dau
conjugates bind to the GnRH-receptor in a specific manner.
However, the binding affinity data of the conjugates
cannot explain alone the results of their in vitro antitumor activ-
ity.
Cellular uptake of the bioconjugates on
MCF-7 human breast and HT-29 human
colon cancer cells by flow cytometry
The cellular uptake of the GnRH-III–drug conjugates was
studied by flow cytometry on HT-29 and MCF-7 cancer cells
(Figure 4). Due to their poor solubility in cell culture medium,
the cellular uptake of the D-Trp containing compounds 3 and 6
was not investigated. The other conjugates were utilized in con-
centrations between 0.15–160 µM. For determination of the cel-
lular uptake exclusively living cells were exploited. Because of
the relatively low fluorescence intensity of Dau conjugates, on
both cell lines a concentration of at least 2.5 µM was necessary
to observe an increased uptake of the bioconjugates. In case of
HT-29 cells, the two bioconjugates K1 and K2 which were used
as internal standards displayed a higher cellular uptake than the
new candidates. This became particularly obvious at lower con-
centrations (2.5 µM and 10 µM). In accordance with our
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Figure 4: Cellular uptake of the GnRH-III bioconjugates at different concentrations on A) HT-29 and B) MCF-7 cells after 6 h determined by flow
cytometry. Experiments were carried out in duplicates; error bars represent standard deviation.
previous data, the cellular uptake of K2 by HT-29 cells is en-
hanced in comparison to K1 [29,38]. Furthermore, the cellular
uptake by HT-29 cells at 160 µM concentration was higher than
90% for all bioconjugates except compound 5 (83%). The same
effect could be observed on MCF-7 cells, whereby the uptake of
bioconjugate 5 was 76%. At 40 µM, K2 was taken up by MCF-
7 cells more effectively (61.2%) than the other compounds.
Apart from that, bioconjugate 1 displayed a slightly higher
uptake than K1 at 10 µM and 40 µM concentration. In general,
the bioconjugates with 6D-Asp had an improved cellular uptake
in comparison with the corresponding 6D-Glu derivatives.
Furthermore, in contrast to the control bioconjugates K1 and
K2 the two compounds with Lys(Bu) in position 4 (4 and 5)
revealed a declined cellular uptake over the 4Ser counterparts (1
and 2) on both cell lines. The differences in the behavior of the
new compounds might be a result of the changed conformation
of the D-amino acid containing derivatives. Due to the results of
the receptor binding studies, we can assume that the binding site
of the receptor is not essentially disturbed by the converted con-
formation, but it might be possible that the receptor internaliza-
tion is influenced by the structure of the bound ligand.
Considering all these data, we can conclude that the cytostatic
effect is not only influenced by the cellular uptake, but also the
release of the effective metabolite plays an important role. For
instance, the novel bioconjugate 1 provides the highest cellular
uptake over the other D-amino acid containing derivatives, but
the IC50 values are in the same range or even higher than the
IC50 value of the other compounds 2, 4 and 5. It can be assumed
that this effect occurred due to the reduced release of the
smallest Dau-containing metabolite.
Confocal laser scanning microscopy (CLSM)
studies
Next to the quantitative analysis of the cellular uptake by flow
cytometry, the cellular uptake and localization of K1, K2, 1, 2,
4 and 5 were studied on MCF-7 cells by CLSM. After 6 h incu-
bation with the GnRH-III–Dau conjugates (c = 10 µM, 40 µM
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Figure 5: Cellular uptake of bioconjugate K2 (40 µM) visualized by confocal laser scanning microscopy (CLSM) A) after 6 h incubation, daunorubicin
(Dau) accumulates in the nucleus. B) Time dependent localization of bioconjugate K2 after 1 min, 5 min, 10 min, 30 min, 1 h, 2 h, 3 h and 6 h incuba-
tion. C) Co-localization of K2 (40 µM) with lysosomes (CytoPainter Lysosomal Staining Kit) after 5 min incubation. In the early stages of the cellular
uptake the Dau signal is co-localized with the lysosomal staining (scale bars represent 10 µm).
and 160 µM), MCF-7 cells were fixed and prepared for
confocal laser scanning imaging. In order to gain insight into a
possible co-localization with nuclei, DAPI-staining was per-
formed. Images are displayed in BestFit mode to improve visu-
alization of low signals and to optimize the image quality. The
CLSM observations cannot be considered as quantitative analy-
sis but provide qualitative information about subcellular locali-
zation. In case of all investigated compounds and concentra-
tions, the Dau signal could be detected mainly in the nuclei and
in small, cytosolic compartments (Figure 5A, Supporting Infor-
mation File 1, Figures S9–S14) evidencing that the conjugated
daunorubicin reaches its site of action.
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To obtain more detailed information of the cellular mechanism
after internalization, we analyzed the subcellular localization of
one Dau conjugate at different timepoints by using shorter incu-
bation times (Figure 5B). Due to the results achieved by flow
cytometry and cell viability assay K2 was selected for further
investigations. The results indicate that Dau-containing metabo-
lites can be found in high amount in the nuclei after already 10
to 30 minutes, whereas the CLSM images after 1 and 5 minutes
display the Dau signal predominantly in small cytosolic vesi-
cles.
We supposed that the smaller cytosolic compartments seen at
early timepoints might be lysosomes. To prove this assumption,
a lysosomal co-localization study was performed with K2 on
MCF-7 cells. After 5 min incubation, the detected Dau signals
corresponded largely with the signal of the lysosomal stain
revealing a co-localization with lysosomes (Figure 5C). The
remaining vesicles which display only the Dau signal are
assumed to be endosomes. Based on these findings it can be
concluded that our lead compound K2 is uptaken through an
endocytic pathway.
Receptor blockage by triptorelin
In order to investigate if the bioconjugate K2 is uptaken in a re-
ceptor-mediated manner, a competition assay was performed on
MCF-7 human breast cancer cells using an excess of the super-
agonist triptorelin. This GnRH-R binder was also used to prove
the mechanism of action of the Dox–GnRH-I bioconjugate
zoptarelin on Hec-1a and Ishikawa endometrial cancer cells
[14]. To analyze the effect of triptorelin on the cellular uptake
of the GnRH-III bioconjugates, MCF-7 cells were treated
collectively with K2 (fixed concentration of 40 µM) and trip-
torelin (concentration range of 125–1000 µM). Recently,
Gründker et al. reported that triptorelin treatment leads to an in-
creased density of GnRH-I receptors on MCF-7 cells [53].
Hence, our intention was to avoid long term incubation with
triptorelin. The results of the CLSM studies indicate that
1–2 hours are sufficient to obtain substantial Dau uptake, there-
fore cells were treated for 100 min. Afterwards, the cells were
analyzed by flow cytometry displaying a reduction of the cellu-
lar uptake of K2 by an increasing triptorelin concentration
(Figure 6). These results strongly indicate that the internaliza-
tion of the Dau–GnRH-III bioconjugates can be blocked by trip-
torelin suggesting that the cellular uptake occurs in a GnRH-R-
mediated manner.
Conclusion
Our studies demonstrate that the cytostatic effect of drug
bioconjugates, in our case Dau–GnRH-III derivative conjugates,
depend on various cellular events. Thus, the efficiency of DDSs
is not only defined by their stability under physiological condi-
Figure 6: Competitive inhibition of the GnRH-R on MCF-7 cells. Cellu-
lar uptake of the GnRH-III bioconjugate K2 (40 µM) was studied in the
presence of superagonist triptorelin (125–1000 µM) by flow cytometry.
Cells were treated simultaneously with K2 and triptorelin for 100 min.
tions and the selectivity to cancer cells, but also the cellular
uptake of the drug–carrier molecule and the release of the active
agent play an important role.
All investigated compounds exhibit cytostatic effects on HT-29
human colon cancer and MCF-7 human breast cancer cells,
whereby the well-defined lead compound K2 remains our most
promising drug candidate. The six novel GnRH-III-[6D-
Aaa]–Dau conjugates reveal 3–5 times lower antitumor activity
than the parent conjugates. Their antitumor effects are influ-
enced by many factors which counteract each other. Therefore,
no significant difference in IC50 values could be observed. It
turned out that the 4Lys(Bu)-containing conjugates 4 and 5 have
a higher binding affinity to the GnRH receptors in comparison
to the 4Ser-containing ones. Furthermore, the D-Asp deriva-
tives 1 and 4 show slightly improved receptor binding proper-
ties than the D-Glu derivatives 2 and 5 which might be the
reason for the enhanced cellular uptake of the D-Asp conju-
gates. However, our lysosomal degradation studies pointed out
that the digestion of conjugates 1 and 4 is less effective and
results in larger metabolites. These metabolites might have a
reduced DNA intercalating potency than the smallest Dau-
metabolite (H-Lys(Dau=Aoa)-OH) which could be identified in
case of the control peptides K1 and K2. It is worth mentioning
that in case of D-Trp containing conjugates a significant amount
of H-Lys(Dau=Aoa)-OH metabolite was released, however,
other biological study could not be made with them because of
their poor solubility in cell culture medium. Due to this obser-
vation, the conjugates 3 and 6 might be interesting for further
development. Nevertheless, our results provide significant
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information about the influence of the cellular uptake and
the release of the effective metabolite on the efficiency of the
DDS.
Next to these findings, we could systematically specify the re-
ceptor-mediated endocytosis pathway for GnRH-III-[4Lys(Bu),
8Lys(Dau=Aoa)] which is also representative for other
Dau–GnRH-III bioconjugates. Based on our results, we can
assume that the GnRH-III bioconjugates specifically bind the
GnRH-Rs on cancer cells and induce in that way their internal-
ization. Moreover, the outcome of the time dependent localiza-
tion of Dau peptide conjugates or the Dau-containing metabo-
lites can give clear indication for an endocytotic pathway.
Furthermore, we could evident the localization of Dau–GnRH-
III conjugates in lysosomes by lysosomal staining. All CLSM
data attest the intranuclear accumulation of Dau proving the
presence of Dau-containing metabolites on its site of action.
In summary, our findings support the development of new ther-
apeutic approaches based on new cytotoxic peptide conjugates
targeting GnRH receptors in human cancers.
Experimental
Material
All amino acid derivatives and Rink-Amide MBHA resin were
purchased from Iris Biotech GmBH (Marktredwitz, Germany).
Boc-aminooxyacetic acid (Boc-Aoa-OH), aminooxyacetic acid,
scavengers, coupling agents and cleavage reagents (1-hydroxy-
benzotriazole hydrate (HOBt), N,N’-diisopropylcarbodiimide
(DIC), triisopropylsilane (TIS), piperidine, 1,8-diazabi-
cyclo[5.4.0]undec-7-ene (DBU), trifluoroacetic acid (TFA),
diisopropylethylamine (DIPEA), acetic anhydride (Ac2O),
methanol (MeOH), n-butyric anhydride and solvent for HPLC
(acetonitrile (ACN)) were obtained from Sigma-Aldrich Kft
(Budapest, Hungary). Daunorubicin hydrochloride was a gift
from IVAX (Budapest, Hungary). N,N-Dimethylformamide
(DMF), dichloromethane (DCM) and diethyl ether (Et2O) were
purchased from Molar Chemicals Kft (Budapest, Hungary). All
reagents and solvents were of analytical grade or highest avail-
able purity.
Synthesis of oxime bond-linked
GnRH-III–[4Ser/4Lys(Bu), 6Aaa,
8Lys(Dau=Aoa)] bioconjugates
The Dau–GnRH-III derivatives were synthesized by solid phase
peptide synthesis according to Fmoc/t-Bu chemistry on a Rink-
Amide MBHA resin (0.73 mmol/g coupling capacity) followed
by ligation of Dau (oxime bond) in solution. All peptides were
synthesized manually by usage of the following Fmoc-pro-
tected amino acid derivatives: Fmoc-Gly-OH, Fmoc-Pro-OH,
Fmoc-Lys(Mtt)-OH, Fmoc-Lys(Dde)-OH, Fmoc-Trp-OH,
Fmoc-D-Trp-OH, Fmoc-Asp(Ot-Bu)-OH, Fmoc-D-Asp(Ot-
Bu)-OH, Fmoc-D-Glu(Ot-Bu)-OH, Fmoc-His(Trt)-OH and
Fmoc-Ser(t-Bu)-OH. Pyroglutamic acid (Glp or <E) was at-
tached to the peptide chain without any protection. The general
protocol for the synthesis started with DMF-washing
(4 × 1 min), followed by Fmoc deprotection with 2% piperidine,
2% DBU in DMF (4 times; 2 + 2 + 5 + 10 min). The coupling
reaction was performed by using 3 equiv of α-Fmoc-protected
amino acid derivative, 3 equiv DIC and 3 equiv HOBt in DMF
(60 min). After washing with DMF (3 × 1 min) and DCM
(2 × 1 min) the success of the coupling was controlled by ninhy-
drine test. After assembly of the protected decapeptide the Dde
group of 4Lys was removed with 2% hydrazine in DMF
(12 × 5 min) and the peptidyl-resin was washed with DMF
(5 × 1 min). Afterwards, the ε-NH2 amino group was butyry-
lated with 3 equiv butyric anhydride and 3 equiv DIPEA in
DMF (2 h). In the next step, 8Lys(Mtt) was deprotected with
2% TFA in DCM (6 × 5 min). Then the resin-bound peptide
was neutralized with 10% DIPEA in DCM (3 × 5 min) and Boc-
Aoa-OH was coupled for 2 h using DIC, HOBt coupling
reagents (3 equiv each to the amino group). The treatment with
95% TFA, 2.5% TIS and 2.5% water (v/v/v) in the presence of
10 equiv free aminooxyacetic acid as “carbonyl capture”
reagent (2 h, at room temperature (rt)) resulted in the simulta-
neous removal of the side chain protecting groups and the
cleavage of the peptide from the resin [54]. Peptides were iso-
lated by precipitation with ice-cold Et2O, centrifuged, washed
3 times, dissolved in water/ACN (0.1% TFA) 4:1 (v/v) and
lyophilized. Subsequent to the purification of the crude peptides
by RP-HPLC, the solvent was evaporated and Dau was conju-
gated to the aminooxyacetylated 8Lys. The oxime bond forma-
tion was carried out in 0.2 M ammonium acetate buffer
(pH 5.0), at a peptide concentration of 10 mg/mL and 1.3 equiv
Dau [21]. The reaction mixtures were stirred overnight at rt and
then purified by RP-HPLC. The resulting GnRH-III bioconju-
gates were characterized by analytical RP-HPLC and MS.
RP-HPLC
The crude peptides and the bioconjugates were purified on a
KNAUER 2501 HPLC system (H. Knauer, Bad Homburg,
Germany) using a preparative Phenomenex Luna C18(2)
column (100 Å, 10 µm, 250 mm × 21.2 mm) (Torrance, CA,
USA). Linear gradient elution (0 min 20% B; 5 min 20% B;
50 min 80% B) with eluent A (0.1% TFA in water) and eluent B
(0.1% TFA in ACN/H2O (80:20, v/v)) was used at a flow rate
of 9.5 mL/min. Peaks were detected at 280 nm.
Analytical RP-HPLC was performed on a KNAUER 2501
HPLC system using a Phenomenex Luna C18 column (100 Å,
5 µm, 250 mm × 4.6 mm) as a stationary phase. Linear gradient
elution (0 min 0% B; 5 min 0% B; 50 min 90% B) at a flow rate
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of 1 mL/min with eluents described above. Peaks were detected
at 220 nm.
Mass spectrometry
Electrospray ionization (ESI) mass spectrometric analyses were
carried out on an Esquire 3000+ ion trap mass spectrometer
(Bruker Daltonics, Bremen, Germany). Spectra were acquired
in the 50–2500 m/z range. Samples were dissolved in a mixture
of ACN/water (1:1, v/v) and 0.1% formic acid.
Liquid chromatography–mass spectrometry (LC–MS) was
carried out on the same spectrometer equipped with an Agilent
1100 HPLC system and a diode array detector (Agilent, Wald-
bronn, Germany). Peptides were separated on a Supelco C18
column (150 mm × 2.1 mm, 3 µm) (Hesperia, CA) using a
linear gradient from 2–70% B in 25 min (eluent A: ddH2O,
0.1% HCOOH; eluent B: 80% ACN, 0.1% HCOOH at a flow
rate of 0.2 mL/min). Spectra were recorded in positive ion mode
in the 100–2500 m/z range.
Electronic circular dichroism spectroscopy
Electronic circular dichroism (ECD) spectra were recorded on a
Jasco J-810 (Jasco International Co., Ltd., Tokyo, Japan) spec-
tropolarimeter at 25 °C in quartz cells of 0.02 cm path length,
under constant nitrogen flush. The instrument was calibrated
with 0.06% (w/v) ammonium-D-camphor-10-sulfonate
(Katayama Chemical, Japan) in water. The bioconjugates were
dissolved in water (c = 340 µM). The spectra show averages of
six scans in a wavelength range of 185–260 nm. The results
were expressed in terms of mean molar el l iptici ty
(deg cm2 dmol−1) after subtracting the solvent baseline.
Degradation of GnRH-III bioconjugates in rat
liver lysosomal homogenate
The rat liver lysosomal homogenate was prepared as previously
described [26]. The protein concentration was determined by
Qubit Protein Assay Kit according to the manufacturer’s
protocol (ThermoFisher Scientific, Waltham, MA, USA). The
bioconjugates were dissolved in ddH2O to a concentration of
5 µg/µL. The reaction was carried out in 0.2 M NaOAc buffer
(pH 5), with an identical concentration of bioconjugate and rat
liver lysosomal homogenate (0.25 µg/µL). The reaction mix-
tures were incubated at 37 °C and aliquots of 15 µL were taken
at 5 min, 1 h, 2 h, 4 h, 8 h and 24 h and quenched with 2 µL of
acetic acid. The analysis of the samples was performed by
LC–MS.
Cell culture
MCF-7 human breast adenocarcinoma cells were cultured in
Dulbecco’s Modified Eagle Medium (DMEM, Lonza, Basel,
Switzerland), supplemented with 10% (v/v) fetal bovine serum
(FBS, Lonza), L-glutamine (2 mM, Lonza), non-essential amino
acids (NEAA, Sigma-Aldrich Kft), sodium pyruvate (1 mM,
Lonza) and penicillin-streptomycine (Lonza). HT-29 human
colon adenocarcinoma cells were cultured in RPMI-1640
(Lonza), supplemented with FBS, L-glutamine and penicillin-
streptomycine. Cells were maintained in plastic culture dishes at
37 °C with a humidified atmosphere containing 5% CO2/
95% air.
Stability of GnRH-III bioconjugates in cell
culture medium
The GnRH-III bioconjugates were dissolved in water to a con-
centration of 2.5 mg/mL followed by the dilution with serum-
free cell culture medium (final bioconjugate concentration:
0.5 mg/mL). The mixtures were incubated at 37 °C for 24 h and
samples of 50 µL were directly monitored by RP-HPLC at time
points 0 h, 1 h, 2 h, 6 h and 24 h.
In vitro cytostatic effect studies
Cells were seeded to 96-well plates (Sarstedt, Nümbrecht,
Germany, 5 × 103 cells/well) one day prior to the treatment in
complete cell medium. Cells were treated with bioconjugates in
serum-free medium (concentration range 0.07−150 µM, control
wells were treated with serum-free medium). After 24 h, cells
were washed two times with serum-free medium and were incu-
bated in complete medium for 48 h. Cytostasis detection was
performed using alamarBlue reagent® (ThermoFisher Scien-
tific) according to the manufacturer’s instructions. Fluores-
cence was detected using Synergy H4 multi-mode microplate
reader (BioTek, Winooski, VT, USA), excitation and emission
wavelengths were set to 570 and 620 nm, respectively.
Cytostasis was measured using 4 parallels, each experiment was
repeated twice. Cytostatic effect (and IC50 values) were calcu-
lated by using nonlinear regression (sigmoidal dose response)
with Origin Pro8 (OriginLab Corp., Northampton, MA, USA.).
Cellular uptake determination by flow
cytometry
For determining cellular uptake of the bioconjugates, cells were
seeded to 24-well plates (Sarstedt) one day prior to the experi-
ment (105 cells/well) in complete cell medium. Treatment with
Dau-conjugated peptides was performed in serum-free culture
medium for 6 h, concentrations ranging from 0.15–160 µM. In
case of the competitive inhibition of the GnRH-Rs, MCF-7 cells
were simultaneously treated with triptorelin and K2 for
100 min, whereby triptorelin was used in a concentration range
of 125–1000 µM and K2 was applied in a fixed concentration
of 40 µM. After treatment, cells were washed two times with
serum-free medium and one time with HPMI medium (contain-
ing 100 mM NaCl, 5.4 mM KCl, 0.4 mM MgCl2, 0.04 mM
CaCl2, 10 mM Hepes, 20 mM glucose, 24 mM NaHCO3 and
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5 mM Na2HPO4 at pH 7.4) and trypsinized for 10 min at 37 °C.
Trypsinization was stopped by HPMI medium supplemented
with 10% FBS. Detached cells were centrifuged at 216g for
5 min at 4 °C and the supernatant was removed. Cells were
resuspended in HPMI medium, intracellular fluorescence inten-
sity (that is proportional to the cellular uptake) was monitored
by flow cytometer BD LSR II (BD Bioscience, Franklin Lakes,
NJ, USA). Data were analyzed by FACSDiVa (BD Bioscience)
5.0 software.
Confocal microscopy imaging
Cells were seeded to cover glass containing (thickness 1, Assis-
tant, Karl Hecht GmbH & Co KG, Sondheim/Rhön Germany)
24-well plates one day prior to the experiment in complete cell
medium. Treatment was performed in serum-free medium for
the indicated incubation time. Cells were washed two times
with phosphate buffered saline (PBS) and fixed by 4% para-
formaldehyde for 20 min at 37 °C. After three times washing
with PBS, nuclei were stained by 4′,6-diamidine-2-phenylin-
dole dihydrochloride (DAPI, 0.2 µg/mL, dissolved in PBS,
Sigma-Aldrich Kft.) for 15 min. After washing, cover glasses
were mounted to microscopy slides (VWR International,
Debrecen, Hungary) by Mowiol® 4-88 mounting medium
(Sigma-Aldrich Kft.). In case of the lysosomal co-localisation
study, lysosomes were stained in living cells before treatment
with peptide K2 by CytoPainter Lysosomal Staining Kit - Deep
Red Fluorescence (abcam, Cambridge, UK), according to the
manufacturer’s instructions. Confocal microscopy was carried
out using a Zeiss LSM 710 system (Carl Zeiss Microscopy
GmbH, Jena, Germany) with a 40× oil objective. Images were
processed by software ZEN Lite (Carl Zeiss Microscopy
GmbH).
Radioligand binding studies
Radiolabeled triptorelin was used for displacement studies to
evaluate the binding affinity of the conjugates K1, K2, 1, 2, 4
and 5 to GnRH-RI on human pituitary and human prostate
cancer cells. Tissue samples derived by autopsy from normal
human pituitary (anterior lobe) and human prostate cancer cells
were obtained from a patient at the time of initial surgical treat-
ment. The collection and the use of these specimens for our
studies are approved by the local Institutional Ethics
Committee. Membranes for receptor binding studies have been
prepared as previously described [29,51,52,55]. Radioiodinated
GnRH-I agonist triptorelin was prepared by chloramines-T
method and purified by RP-HPLC [29,51,52,56]. This radioli-
gand has been well-characterized and shows high-affinity
binding to human and rat pituitaries as well as human breast,
prostate, and other cancers [51,52]. The binding affinities of the
nonradio-labeled GnRH-III bioconjugates to GnRH-RI were de-
termined by displacement of [125I]-GnRH-I-[6D-Trp] per-
forming an in vitro ligand competition assay as recently re-
ported [29,51,52]. Hereby, membrane homogenates which
contain 50–160 mg protein were incubated in duplicate or tripli-
cate with 60–80,000 cpm [125I]-GnRH-I-[6D-Trp] and increas-
ing concentration (1 pM–1 µM) of nonradioactive bioconju-
gates as competitors in a total volume of 150 mL of binding
buffer. After incubation, 125 mL aliquots of suspension were
transferred onto the top of 1 mL of ice-cold binding buffer
which contained 1.5% bovine serum albumin in siliconized
polypropylene microcentrifuge tubes (Sigma-Aldrich Kft.). The
tubes were centrifuged at 12,000g for 3 min at 4 °C (Beckman
J2-21M, Beckman Coulter, Inc., Brea, CA). Supernatants were
aspirated and the bottoms of the tubes containing the pellet were
cut off and counted in a gamma counter. Protein concentration
was determined by the method of Bradford using a Bio-Rad
protein assay kit (Bio-Rad Laboratories, USA). The LIGAND-
PC computerized curve-fitting program of Munson and
Rodbard was used to determine the receptor binding character-
istics and IC50 values [29,51,52].
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